retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, Unapproved weight loss drug retatrutide

However, variability in GI physiology and safety constraints limit universal success

Treatment decisions should be based on metabolic benefits and overall risk-benefit assessment with your healthcare provider

Here are some of the primary advantages: Blood Sugar Control: For people with Type 2 diabetes, GLP-1 therapy offers a reliable and effective way to regulate blood glucose levels

But as enthusiasm surges among recreational athletes and biohackers alike, experts warn that the science has yet to catch up with the hype and that the biggest risks may not be the ones people expect Walk into almost any gym today and youll hear conversations that would have seemed out of place just a few years ago